Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds
SOUTH EASTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) — Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced that the Company will host a teleconference to discuss the recent strategic acquisition of natural health and wellness innovator Uncle Bud’s (“UB”) in an all-stock transaction. In particular, the Company will discuss its current, in-process move to new, more efficient manufacturing space; the integration plan of the Uncle Bud’s team and product offerings into PBIO; and the significant growth expected from new UltraShear processed nanoemulsion products, which are expected to catapult the Company’s total revenue by 5X to about $10M in 2024.
Related news for (PBIO)
- Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray
- Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET
- Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET
- Uncle Bud’s Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness
- Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”